{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:28:32Z","timestamp":1792625312163,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000292","name":"Cystic Fibrosis Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000292","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jcf.2025.01.010","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T15:05:39Z","timestamp":1736867139000},"page":"787-791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Longer term follow-up of abdominal symptoms (CFAbd-Score) after initiation of Elexacaftor \/ Tezacaftor \/ Ivacaftor in adults with cystic fibrosis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8957-1018","authenticated-orcid":false,"given":"L.R.","family":"Caley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gillgrass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zagoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8967-2991","authenticated-orcid":false,"given":"H.","family":"Saumtally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Duckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"White","family":"H","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G.","family":"Mainz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7723-1868","authenticated-orcid":false,"given":"D.G.","family":"Peckham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10059","key":"10.1016\/j.jcf.2025.01.010_bib0001","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jcf.2025.01.010_bib0002","doi-asserted-by":"crossref","first-page":"++","DOI":"10.1101\/cshperspect.a009753","article-title":"The cystic fibrosis intestine","volume":"3","author":"De Lisle","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"8","key":"10.1016\/j.jcf.2025.01.010_bib0003","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/thorax-2023-220100","article-title":"A refresh of the top 10 research priorities in cystic fibrosis","volume":"78","author":"Rowbotham","year":"2023","journal-title":"Thorax"},{"issue":"19","key":"10.1016\/j.jcf.2025.01.010_bib0004","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jcf.2025.01.010_bib0005","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.01.010_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.877118","article-title":"Elexacaftor-tezacaftor-ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-score","volume":"13","author":"Mainz","year":"2022","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.jcf.2025.01.010_bib0007","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jcf.2023.10.001","article-title":"Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged \u226512 years - the RECOVER study","volume":"23","author":"Mainz","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.01.010_bib0008","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S1569-1993(23)00331-4","article-title":"EPS5.01 Change in gut microbiota following elexacaftor\/tezacaftor\/ivacaftor (ETI) therapy: preliminary analysis","volume":"22","author":"Caley","year":"2023","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1016\/j.jcf.2025.01.010_bib0009","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jcf.2024.08.001","article-title":"A longitudinal study assessing the impact of elexacaftor\/tezacaftor\/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI)","volume":"23","author":"Yule","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2025.01.010_bib0010","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jcf.2023.01.010","article-title":"Diabetes is associated with increased burden of gastrointestinal symptoms in adults with cystic fibrosis","volume":"22","author":"Caley","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2025.01.010_bib0011","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jcf.2023.06.010","article-title":"Body mass index and nutritional intake following Elexacaftor\/Tezacaftor\/Ivacaftor modulator therapy in adults with cystic fibrosis","volume":"22","author":"Caley","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2025.01.010_bib0012","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jcf.2025.01.010_bib0013","doi-asserted-by":"crossref","first-page":"17465","DOI":"10.1038\/s41598-017-17302-4","article-title":"Relation of ultrasound findings and abdominal symptoms obtained with the CFAbd-score in cystic fibrosis patients","volume":"7","author":"Tabori","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jcf.2025.01.010_bib0014","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40271-019-00361-2","article-title":"Validity and reliability of a novel multimodal questionnaire for the assessment of abdominal symptoms in people with cystic fibrosis (CFAbd-Score)","volume":"12","author":"Jaudszus","year":"2019","journal-title":"Patient"},{"key":"10.1016\/j.jcf.2025.01.010_bib0015","unstructured":"Administration USDoHaHSFaD, GUIDANCE DOCUMENT: patient-reported outcome measures: use in medical product development to support labeling claims. 2009."},{"issue":"7","key":"10.1016\/j.jcf.2025.01.010_bib0016","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jclinepi.2010.02.006","article-title":"The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes","volume":"63","author":"Mokkink","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.jcf.2025.01.010_bib0017","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s10620-022-07812-1","article-title":"Cystic fibrosis-related gut dysbiosis: a systematic review","volume":"68","author":"Caley","year":"2023","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jcf.2025.01.010_bib0018","doi-asserted-by":"crossref","unstructured":"Mainz, J.G., et al., Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor\/tezacaftor\/ivacaftor using the novel CFAbd-day2day questionnaire. 2023. 14.","DOI":"10.3389\/fphar.2023.1167407"},{"issue":"2","key":"10.1016\/j.jcf.2025.01.010_bib0019","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.01.010_bib0020","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/MPG.0000000000003357","article-title":"Abdominal symptoms assessed with the CFAbd-score are associated with intestinal inflammation in patients with cystic fibrosis","volume":"74","author":"Jaudszus","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10.1016\/j.jcf.2025.01.010_bib0021","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/gutjnl-2011-300563","article-title":"Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer","volume":"61","author":"Andreyev","year":"2012","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.jcf.2025.01.010_bib0022","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000538606","article-title":"Improved nutritional outcomes and gastrointestinal symptoms in adult cystic fibrosis patients treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"42","author":"Stastna","year":"2024","journal-title":"Dig Dis"},{"issue":"173","key":"10.1016\/j.jcf.2025.01.010_bib0023","first-page":"33","article-title":"Medication adherence to CFTR modulators in patients with cystic fibrosis: a systematic review","author":"Hansen","year":"2024","journal-title":"Eur Respir Rev"},{"issue":"1","key":"10.1016\/j.jcf.2025.01.010_bib0024","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/21556660.2021.1912352","article-title":"Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: analysis of a national specialty pharmacy database","volume":"10","author":"Mehta","year":"2021","journal-title":"J Drug Assess"},{"issue":"20","key":"10.1016\/j.jcf.2025.01.010_bib0025","first-page":"10","article-title":"Heightened mitochondrial respiration in CF cells is normalised by triple CFTR modulator therapy through mechanisms involving calcium","author":"Jarosz-Griffiths","year":"2024","journal-title":"Heliyon"},{"issue":"9","key":"10.1016\/j.jcf.2025.01.010_bib0026","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1136\/gutjnl-2021-325177","article-title":"Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet","volume":"71","author":"Vervier","year":"2022","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.jcf.2025.01.010_bib0027","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/advances\/nmac029","article-title":"Dietary Patterns and Gut Microbiota: the Crucial Actors in Inflammatory Bowel Disease","volume":"13","author":"He","year":"2022","journal-title":"Adv Nutr"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:14:16Z","timestamp":1778822056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325000104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1569199325000104"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.01.010","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longer term follow-up of abdominal symptoms (CFAbd-Score) after initiation of Elexacaftor \/ Tezacaftor \/ Ivacaftor in adults with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}